How much revenue does Luoxin Pharmaceuticals Group Stock make?

Luoxin Pharmaceuticals Group Stock reported 2.27 billion CNY in revenue for fiscal year 2025, down 14.2% from 2.65 billion CNY in fiscal year 2024. In Q1 2026 revenue was 582.73 million CNY.

What is Luoxin Pharmaceuticals Group Stock's largest business segment?

Pharmaceutical Industry, with 2.01 billion CNY or 91% of segment revenue in fiscal year 2024. Next: Pharmaceutical Commercial (9%).

Where does Luoxin Pharmaceuticals Group Stock make most of its revenue?

East China: 42% of revenue by region in fiscal year 2024, followed by North China (13%).

What companies are similar to Luoxin Pharmaceuticals Group Stock?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Youcare Pharmaceutical Group Co., Ltd. (688658.SS), Beijing SL Pharmaceutical Co., Ltd. (002038.SZ), Hunan Jiudian Pharmaceutical Co., Ltd. (300705.SZ), Lionco Pharmaceutical Group Co.,Ltd. (603669.SS).

Luoxin Pharmaceuticals Group Stock Co., Ltd. (002793.SZ) Stock

About Luoxin Pharmaceuticals Group Stock Co., Ltd.

Luoxin Pharmaceuticals Group Stock Co., Ltd. engages in the research and development, production, and sales of pharmaceutical products in China. The company provides anti-infective active pharmaceutical ingredients(APIs), antiviral APIs, respiratory and digestive system, nervous and endocrine system, cardiovascular system, oncology, and anti-allergic APIs and intermediates, as well as antipyretic,...

At a glance

Luoxin Pharmaceuticals Group Stock reported revenue of 2.27 billion CNY for fiscal year 2025, down 14.2% from fiscal year 2024, and net income of -288.58 million CNY. In Q1 2026 (the quarter ended March 31, 2026) revenue was 582.73 million CNY, up 20.7% from a year before. Its largest business segment, Pharmaceutical Industry, brought in 91% of segment revenue in fiscal year 2024; East China was the largest region with 42%.

Figures from company filings; latest fiscal year ended December 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.